Yahoo
NasdaqCM - Nasdaq Real Time Price USD

Harvard Bioscience, Inc. (HBIO)

8.90 +0.10 (+1.14%)
At close: October 30 at 4:00:01 PM EDT

Key Executives

Amounts are as of December 31, 2025 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
Name Title Pay Exercised Year Born
Mr. John Duke
President, CEO, Director & Member of Scientific Advisory Board 581.27k -- 1971
Mr. Mark T. Frost
CFO, Treasurer, Principal Financial Officer & Principal Accounting Officer 425.98k -- 1963
Ms. Lori Packer
Vice President of Global People Operations -- -- --
Mr. David Panzarella
Senior Vice President of Commercial -- -- --
Kathryn Flynn
Corporate Controller -- -- --
David Sirois
Director of Corporate Accounting & SEC Reporting -- -- --

Harvard Bioscience, Inc.

84 October Hill Road
Suite 10
Holliston, MA 01746
United States
508 893 8999 https://www.harvardbioscience.com
Sector: 
Healthcare
Full Time Employees: 
316

Description

Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the Americas, Europe, the Middle East, Africa, Asia, and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings. It provides preclinical products that includes platform to assess physiological data from organisms for research, drug discovery, and drug development services comprising implantable and externally worn telemetry systems for use in research to collect cardiovascular, central nervous system, respiratory, and metabolic data; behavioral products; isolated organ and surgical products, instruments and accessories for tissue, and organ-based lab research, including surgical products, infusion systems, and behavior research systems; turn-key respiratory system solutions, including plethysmograph chambers, data acquisition hardware, physiological signal analysis software, and final report generation; inhalation and exposure systems; and GLP-capable data acquisition and analysis systems. The company markets its products through websites and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories; and contract research organizations and academic laboratories. It primarily sells its products under the Harvard Apparatus, Biochrom, BTX, HEKA, KD Scientific, MCS, Warner, DSI, Panlab, Hugo Sachs, and Buxco brands. Harvard Bioscience, Inc. was founded in 1901 and is based in Holliston, Massachusetts.

Corporate Governance

Harvard Bioscience, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

November 10, 2026 at 1:30 PM UTC

Harvard Bioscience, Inc. Earnings Date

Recent Events

August 11, 2026 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

June 10, 2026 at 12:00 AM UTC

S-8: Offering Registrations

June 2, 2026 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

May 27, 2026 at 12:00 AM UTC

SD: Specialized Disclosure Report filed pursuant to Section 1502 of the Dodd-Frank Wall Street Reform and Consumer Protection Act relating to the use of conflict minerals (Rule 13p-1)

May 12, 2026 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

April 21, 2026 at 12:00 AM UTC

DEF 14A: Proxy Statements

March 17, 2026 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

March 13, 2026 at 12:00 AM UTC

10-K: Periodic Financial Reports

March 12, 2026 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

March 10, 2026 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

Related Tickers

Mobilize your Website
View Site in Mobile | Classic
Share by: